特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
925307

世界の細胞ベースの免疫療法市場:成長、動向、予測 (2020~2025)

Cell Based Immunotherapy Market - Growth, Trends, and Forecast (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 120 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
世界の細胞ベースの免疫療法市場:成長、動向、予測 (2020~2025)
出版日: 2020年02月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 120 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

細胞ベースの免疫療法市場は、予測期間中に15.5%のCAGRを登録すると予想されます。癌の有病率の上昇、技術の進歩、および新規の標的ベースの抗癌療法の開発は、細胞ベースの免疫療法市場の成長を促進する主な要因となっています。

当レポートでは、世界の細胞ベースの免疫療法市場を調査し、市場の概要、地域別の市場規模の推移と予測、市場動向、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査の前提条件
  • 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場成長要因
    • 癌の有病率の上昇
    • 標的ベースの抗癌療法の開発における技術進歩
    • さまざまな細胞ベースの免疫療薬の発売と承認
  • 市場の抑制要因
    • 高い技術コスト
    • 発展途上市場における意識欠如
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤーの交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 競争の激化

第5章市場セグメンテーション

  • 治療法別
    • 自己細胞免疫療法
    • キメラ抗原受容体(CAR)T細胞療法
    • 樹状細胞ベースのワクチン療法
  • 一次指示
    • B細胞悪性腫瘍
    • 前立腺がん
    • 腎細胞がん
    • 肝臓がん
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ地域
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Novartis AG
    • Gilead Sciences, Inc (Kite Pharma)
    • Apac Biotech
    • Dendreon Pharmaceuticals LLC
    • JW CreaGene Co., Ltd
    • Green Cross Corp (GC Pharma)

第7章 市場機会および将来動向

目次
Product Code: 67840

The Cell-Based Immunotherapy Market is expected to register a CAGR of 15.5% during the forecast period. Cellular immunotherapy also known as adoptive cell therapy is a form of treatment that uses the cells of the immune system to treat cancer.

The immune system is capable of recognizing and eliminating cells that are infected or damaged or cancerous. Immune cells known as killer T cells act against cancerous cells, due to their ability to bind to markers known as antigens on the surface of cancer cells. Cellular immunotherapies utilize the natural ability of the killer T cells and make them fight against cancer cells. Sometimes these T cells get activated before they can effectively kill cancer cells and might not exist in enough numbers to act against cancer cells. In order to address these issues, tumor-infiltrating lymphocyte (TIL) is one form of cell-based immunotherapy. CAR T-cell therapy is another form of cell-based immunotherapy that involves re-engineering a patient's own T-cells to recognize and fight against cancer and these T-cells are genetically altered to express artificial receptors which enable the T-cells to bind to a specific antigen on the patient's tumor cells and kill them.

In the year 2018 World Health Organization (WHO) estimated 18.1 million new cases of cancer and approximately 9.6 million deaths worldwide. In addition, one in 5 men and one in 6 women globally develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease. Rising prevalence of cancer, technological advancement, and the development of novel target-based anti-cancer therapies are the key driving factors in the cell-based immunotherapy market.

Key Market Trends

Chimeric Antigen Receptor (CAR) T-Cell Therapy Segment is Expected to Hold a Major Market Share in the Cell Based Immunotherapy Market

  • Chimeric antigen receptor (CAR) T-cell therapy is a major advancement in cancer treatment. In this therapy, patient's own T cells are genetically engineered to express an artificial receptor that binds a tumor antigen. CAR-T cell therapy act against CD19 coded cancer antigens for the treatment of B cell cancers. Yescarta and Kymriah represent recently approved CAR T-cell therapy products indicated for the treatment of B cell malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, mantle cell lymphoma, chronic lymphoid leukemia and diffuse large B-Cell lymphoma.
  • According to the International Agency for Research on Cancer (IARC), by the year 2040, it is estimated that new cases will cancer to grow to 27.5 million per year. In addition, the global cancer burden is anticipated to increase by 70% in the next 20 years.
  • Chimeric Antigen Receptor (CAR) T-Cell Therapy segment holds a significant market share in the cell-based immunotherapy market and is anticipated to show a similar trend over the forecast period.
  • Rising prevalence of cancer, technological advancement in developing target-based anti-cancer therapies and adoption of cell-based therapy is increased for the therapeutic purpose are the key driving factors in the chimeric antigen receptor (CAR) T-cell therapy segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global cell-based immunotherapy market due to the rising prevalence of cancer and the growing awareness of cell-based therapies in this region. According to the Disease Control and Prevention (CDC), nearly 245,000 cases of breast cancer in women and about 2,200 are diagnosed in men each year in the United States, approximately 41,000 women and 460 men in the United States die each year from breast cancer. Furthermore, ongoing research in cancer treatment, adoption of advanced technologies in cell-based therapies and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Cell Based Immunotherapy Market is consolidated competitive and consists of few major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Novartis AG, Gilead Sciences, Inc (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co., Ltd and Green Cross Corp (GC Pharma).

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Cancer
    • 4.2.2 Technological Advancement in Developing Target Based Anti-cancer Therapies
    • 4.2.3 Launches and Approval of Different Cell-based Immunotherapy Drugs
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Technology
    • 4.3.2 Lack of Awareness in the Developing Markets
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Therapy
    • 5.1.1 Autologous Cellular Immunotherapy
    • 5.1.2 Chimeric Antigen Receptor (CAR) T-Cell Therapy
    • 5.1.3 Dendritic Cell-based Vaccine Therapy
  • 5.2 By Primary Indication
    • 5.2.1 B-cell Malignancies
    • 5.2.2 Prostate Cancer
    • 5.2.3 Renal Cell Carcinoma
    • 5.2.4 Liver Cancer
    • 5.2.5 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Novartis AG
    • 6.1.2 Gilead Sciences, Inc (Kite Pharma)
    • 6.1.3 Apac Biotech
    • 6.1.4 Dendreon Pharmaceuticals LLC
    • 6.1.5 JW CreaGene Co., Ltd
    • 6.1.6 Green Cross Corp (GC Pharma)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.